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Recent genome-wide association studies have
linked common variants in the human genome to Par-
kinson’s disease (PD) risk. Here we show that the
consequences of variants at 2 such loci, PARK16
and LRRK2, are highly interrelated, both in terms of
their broad impacts on human brain transcriptomes
of unaffected carriers, and in terms of their associa-
tions with PD risk. Deficiency of the PARK16 locus
gene RAB7L1 in primary rodent neurons, or of
a RAB7L1 ortholog in Drosophila dopamine neurons,
recapitulated degeneration observed with expres-
sion of a familial PD mutant form of LRRK2, whereas
RAB7L1 overexpression rescued the LRRK2 mutant
phenotypes. PD-associated defects in RAB7L1 or
LRRK2 led to endolysosomal and Golgi apparatus
sorting defects and deficiency of the VPS35 compo-
nent of the retromer complex. Expression of wild-
type VPS35, but not a familial PD-associated mutant
form, rescued these defects. Taken together, these
studies implicate retromer and lysosomal pathway
alterations in PD risk.
INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative
disorder of aging, characterized by slowed movements and
a distinctive tremor at rest (Lang and Lozano, 1998). Defining
pathological features of the disease include neurodegeneration
that is most prominent among midbrain dopamine neurons
(DNs) in the substantia nigra (SN) and Lewy body protein aggre-
gates that are composed in part of alpha-synuclein (a-syn)
protein. As the course of PD is thought to last decades, and as
at the time of autopsy the vast majority of DNs are long lost,
the molecular pursuit of initial etiological events has proven
difficult.In rare inherited familial forms of PD, specific causative muta-
tions have been identified, and this has significantly advanced
the field (Abeliovich and Flint Beal, 2006; Hardy et al., 2006).
For instance, autosomal dominantly inherited mutations in
a-syn, including missense mutations and triplication of the
locus, lead to a familial PD variant, implicating a-syn directly
in the disease process. Another familial genetic cause of PD is
the presence of autosomal dominantly inherited mutations in
the leucine-rich repeat kinase-2 (LRRK2) protein, which encodes
a large multidomain protein with GTPase and kinase activities.
Although the precise functions of a-syn and LRRK2 in neurons
remain to be determined, both proteins have been broadly impli-
cated in intraneuronal protein sorting. a-Syn mutations have
been reported to modify synaptic vesicle kinetics (Abeliovich
et al., 2000) as well as trafficking to the Golgi apparatus in a
variety of model systems (Cooper et al., 2006; Thayanidhi
et al., 2010), whereas LRRK2mutations are implicated in defec-
tive lysosomal protein degradation and macroautophagy, which
is a cellular process that delivers cytosolic proteins and protein
aggregates to the lysosome (Dodson et al., 2012; Heo et al.,
2010; MacLeod et al., 2006), and Golgi apparatus integrity (Stafa
et al., 2012). The recent identification of rare autosomal dominant
familial PD mutations in VPS35 (Vilarin˜o-Gu¨ell et al., 2011; Zim-
prich et al., 2011), which encodes a component of the retromer
complex that guides protein sorting from the endosome-lyso-
some degradation pathway retrogradely to the Golgi apparatus
(Bonifacino and Hurley, 2008; Skinner and Seaman, 2009;
Seaman et al., 1998), suggests that defective protein sorting in
vesicular compartments may play a role in PD.
Several genome-wide association studies (GWAS) have
described common genetic variants (at single nucleotide poly-
morphisms [SNPs]) that modify PD risk in nonfamilial ‘‘sporadic’’
cases (Hamza et al., 2010; Simo´n-Sa´nchez et al., 2009; Lill et al.,
2012). Strikingly, a subset of these common variants lie within
genomic loci previously associated with familial disease, such
as a-syn or LRRK2, supporting the notion that common patho-
genic pathways underlie familial and sporadic forms of PD.
However, mechanisms that underlie the impact of nonfamilial
genetic loci on PD risk, or that relate the functions of such loci
to familial PD genes, remain unclear.Neuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc. 425
Figure 1. LRRK2 and PARK16 PD Risk-Associated Variants Function in a Common Genetic Pathway
(A) PD risk-associated variants exert functional effects in the CNS of unaffected individuals that is assessed in terms of a global transcriptome impact. Similar to
the one observed in PD-affected brain, it may reflect a predisease prodromal state.
(B) Schematic of GPI analysis. PD risk-associated genotypes at two independent loci (upper panels) are hypothesized to differentially alter the function of a nearby
gene (red star in middle panel). This secondarily impacts the brain transcriptome (lower panels), with significant overlap for different PD-risk genotype shows.
(C) Hierarchical clustering dendrogram shows that the gene expression signatures across seven PD-associated variant GPIs (‘‘Risk GPI’’; in unaffected cerebral
cortex Brodmann area 9 [BA9]) are most similar to the signatures seen in PD brain (BA9 or substantia nigra [SN] in red) rather than in other CNS diseases such as
Alzheimer’s disease, Huntington’s disease, bipolar disorder, or schizophrenia. A total of 352 gene transcript expression patterns—corresponding to the inter-
section of the PD risk variants GPIs (Figures S1A–S1C)—were interrogated. Clustering was performed using Pearson’s distance with complete linkage (see
Experimental Procedures).
(D) Genetic interaction between PARK16 and LRRK2 alleles revealed by GPI analysis in 185 unaffected brain samples (GEO GSE15222 ‘‘Initial’’) and in an
independent cohort of 143 unaffected brain samples (GEOGSE15745, ‘‘Replication’’), as established by the interaction factor between pairs of GPIs as indicated,
(legend continued on next page)
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s DiseaseHere we describe a series of human brain transcriptome,
human genetic, and cell biological studies, that together impli-
cate a PD-associated genetic and cellular pathway. RAB7L1—
one of five genes within the PARK16 nonfamilial PD risk-associ-
ated locus—functions together with LRRK2 to impact nonfamilial
PD risk in the human population; this genetic interaction is
apparent even in unaffected individuals who carry both risk
alleles, as quantified in terms of a broad transcriptomic analysis
of brain gene expression. Similarly, these genes together modify
neuronal survival and neurite integrity in model systems. At
a cellular level, defects in this PD-associated RAB7L1-LRRK2
pathway lead to abnormal lysosomal structures and defective
retromer complex function, that normally links the endolysoso-
mal protein degradation system with the Golgi apparatus (Boni-
facino and Hurley, 2008; Skinner and Seaman, 2009; Seaman
et al., 1998). Consistent with a role for such cellular defects in
disease pathology, mutations in a retromer complex component,
VPS35, have recently been associated with rare forms of auto-
somal dominantly inherited familial PD (Vilarin˜o-Gu¨ell et al.,
2011; Zimprich et al., 2011).
RESULTS
LRRK2 and PARK16 PD Risk Variants Impart a Common
Brain Transcriptome Impact
We sought an unbiased and systematic approach to assess the
phenotypic impacts of common genetic variants associated with
PD risk, particularly in brain tissue from yet unaffected carriers
(Figure 1A), in order to circumvent the limitations of the analysis
of diseased patient autopsy tissue. To this end, we compared
the transcriptome-wide gene expression profiles of brain
tissue samples from cohorts of unaffected individuals who share
either a risk or a protective allele at any given PD risk SNP (Fig-
ure 1B). Such a global phenotypic impact (GPI) quantifies the
effect of disease risk variants onto the transcriptome-wide
gene expression profile in brain. A key aspect of the GPI analysis
herein is that we focus on tissue from unaffected individuals, in
hope of avoiding secondary effects of disease pathology such
as cell loss.
We assessed the transcriptome-wide GPI at 7 PD-associated
loci (SNCA, LRRK2, MAPT, HLA-DRA, PARK16, LAMP3, STK39;
Table S1 available online) (Simo´n-Sa´nchez et al., 2009) in a publi-
cally available gene expression data set from cerebral cortex
autopsy brain tissue of 185 individuals not apparently affected
by a neurodegenerative disease (Gene Expression Omnibus
[GEO] data set GSE15222). The GPIs of the seven loci revealed
a high degree of overlap in terms of the identity of transcripts
altered in expression level and the valence of such alterations:in a linear regression model (see Experimental Procedures). The p value (‘‘p’’) asso
Results combined across both cohorts presented (‘‘Combined’’) with the resultin
(E) The PARK16 genotypemodifies LRRK2-associated risk in sporadic PD. A table
genotype in four independent GWAS cohorts: one of Ashkenazi Jews (AJ, n = 417
(F) Manhattan plot of the Chr1 region reported as a modifier of age of disease on
evaluated for 74 SNPs in four independent sporadic PDGWAS data sets. The x ax
p value for epistasis of each SNP with the PD risk SNP rs11176052 at the LRRK2
most significant association (p = 4.6 E-6; red line represents the significance thr
See also Figure S1 and Tables S1, S2, and S3.genes were coordinately altered in their expression by each of
the seven PD-associated loci (over 15-fold greater than ex-
pected by chance; p = 1.5E-5 by resampling statistics; Figures
S1A and S1B; Table S2). This observation of an overlapping
GPI for these seven PD-associated loci wasmoreover confirmed
in an additional independent data set of cerebral frontal cortex
autopsy brain tissue of 143 individuals (p = 1.6 E-3 by resampling
statistics; derived from GEO data set GSE15745).
Function annotation was performed on the gene expression
changes that underlie the common GPIs among PD risk variants.
Strikingly, among the annotated gene sets most significantly
reduced in expression are ‘‘mitochondria’’ functions (Figures
S1C and S1D), consistent with the well-described association
of defects in mitochondria with PD pathology (Zheng et al.,
2010). Furthermore, the common overlapping transcriptomic
signature of gene expression changes associated with these
seven PD risk variants revealed a patternmost similar to the tran-
scriptome changes observed in the context of PD patient brain
tissue (relative to unaffected brain tissue; Figure S1C), rather
than to other CNS disorders such as Alzheimer’s disease or
schizophrenia (Figure 1C).
LRRK2 and PARK16 Variants Cooperatively Determine
PD Risk
Among the seven analyzed PD risk locus GPIs, those at the
PARK16 and LRRK2 loci were found to be the most similar.
Furthermore, variants at these two loci impacted the transcrip-
tome in a nonadditive manner, signifying a genetic interaction
(as determined by analysis of carriers of both risk variants; Fig-
ure 1D). We thus investigated whether these loci similarly genet-
ically interact in terms of their impact on PD risk: namely, whether
harboring either a risk (or protective) allele at one of these loci
would modify the association of the second locus with PD risk.
In an initial study on an Ashkenazi Jewish (AJ) population, the
effect of a risk-associated variant at the LRRK2 locus was in
fact highly dependent on the presence of the risk variant at the
PARK16 locus, and vice versa (Figure 1E). Such ‘‘epistasis’’
between the LRRK2 and PARK16 loci regarding PD risk was
replicated by reanalysis of three other independent GWAS,
strongly supporting a common mechanism of action (Figure 1E).
Although to our knowledge, prior studies have not reported
genetic interactions with the common sporadic PD risk-associ-
ated variants at the LRRK2 locus, a GWAS of patients who
harbor rare familial LRRK2 mutations identified a broad 15 Mb
region of Chromosome 1 as harboring a genetic modifier of
age of PD onset (Latourelle et al., 2011). We note that this region
encompassed the PARK16 locus. Meta-analysis in four indepen-
dent sporadic PD GWAS data sets (as above) of the 74 identifiedciated with the interaction term as well as its orientation (‘‘Dir.’’) are presented.
g Z-scores and p values for interaction.
presents the odds ratios for PD at the LRRK2 locus as a function of the PARK16
) and three of Caucasians (NGRC, n = 4008; NINDS, n = 537; MAYO, n = 886).
set in familial PD with LRRK2 mutation (Latourelle et al., 2011). Epistasis was
is represents chromosomal location, y axis representslog10 of the combined
locus. The PARK16 locus PD-associated SNP rs823114 (arrow) exhibited the
eshold after correction for multiple testing).
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Figure 2. Overexpression of the PARK16 Locus Gene RAB7L1 Specifically Rescues a LRRK2 Mutant Phenotype
(A) Schematics of the PARK16 locus on chromosome 1.
(B) RAB7L1modifies a LRRK2-associated neurite process length phenotype. Rat primary cortical neuron cultures transfected with a vector expressing G2019S
mutant LRRK2 displayed reduced total neurite length relative to vector alone (cells are cotransfected with GFP for visualization by fluorescence microscopy).
(i and ii) Cotransfection of a wild-type or constitutively active (CA) RAB7L1 expression vector (1 mg/well) along with LRRK2 G2019S (0.5 mg/well) significantly
rescued neurite length; other PARK16 genes—NUCKS1, SLC45A3, PM20D1, and SLC41A1—failed to rescue. CA or inactive (IN) RAB vectors were also tested as
indicated (left panel; GFP-tagged at the N terminus; 1 mg/well). (iii) Knockdown ofRAB7L1 by shRNA vector transfection led to a similar decrease in neurite length
as with LRRK2 G2019S expression. n = 20 neurons in four independent cultures per group. Mean total neurite lengths are displayed; error bars represent SEM.
*p < 0.05; **p < 0.01; ***p < 0.001 for ANOVA followed by Tukey’s HSD post hoc analysis.
See also Figure S2.
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s DiseaseSNP variants within this Chromosome 1 region for epistasis with
the common LRRK2 SNP variant regarding PD risk identified the
PARK16-associated variant as by far the most significantly inter-
acting variant (combined p value for epistasis: 4.6E-6; Figure 1F;
Table S3). Taken together, these data strongly support a genetic
interaction between LRRK2 and PARK16 that initially impacts
human CNS tissue physiology, as reflected by the transcriptome
signature in unaffected carriers, and ultimately favors PD
pathology in a small subset of individuals at risk.
Evidence of a LRRK2-RAB7L1 Pathway
As five candidate genes are present within the PARK16 locus
(SLC45A3, NUCKS1, RAB7L1, SLC41A1, and PM20D1), we
sought to experimentally screen each of these for a functional
interactionwithLRRK2 (Figure 2A).We took advantage of a previ-
ously-described primary rat neuron in vitro culture model, in
which transient expression of familial PD-associated LRRK2
G2019S or R1441C mutant alleles leads to a marked reduction
in neurite process length (MacLeod et al., 2006). Overexpression
of RAB7L1, but not other genes in the PARK16 locus, signifi-
cantly suppressed the LRRK2 mutation-induced neurite length
phenotype (Figure 2B). RAB7L1 did not modify neurite length
in the context of overexpression of wild-type LRRK2 (Figure428 Neuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc.S2A). RAB7L1 is a small cytosolic GTPase, structurally distinct
from RAB7 despite its name (also known as RAB29) (Shimizu
et al., 1997). One of60 small Rab family GTPases in the human
genome, RAB7L1 has previously been shown to localize
primarily to the Golgi apparatus and implicated in vesicular sort-
ing in the context of Salmonella or Hepatitis C infection (Berger
et al., 2009; Spano` et al., 2011). But the function of RAB7L1 in
CNS neurons remains unknown. Orthologs of RAB7L1 in other
organisms, including Caenorhabditis elegans Glo-1 and
Drosophila melanogaster Lightoid, have been implicated in traf-
ficking to lysosome-related organelles (Hermann et al., 2005)
and in the regulation of neurite process length (Grill et al.,
2007), reminiscent of LRRK2 mutant phenotypes (MacLeod
et al., 2006). Thus this gene was of particular interest.
Because GTPases such as RAB7L1 are typically only active in
the GTP-bound state, we generated mutant forms that are
constitutively active (CA; Q67L; this mutation is deficient in
GTPase activity; data not shown) or inactive (IN; T21N; amutation
within the presumptive GTP binding site; data not shown). As
expected, overexpression of the CA RAB7L1, but not IN
RAB7L1, significantly suppressed the LRRK2 mutation-induced
neurite length phenotype. Of other Rab family members, expres-
sion of RAB3A or RAB5A failed to rescue the phenotype,
Neuron
RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s Diseasewhereas RAB7 CA was effective in suppressing the process
length shortening induced by LRRK2 mutation (Figure 2B). In
contrast to RAB7L1 overexpression, knockdown of RAB7L1
alone led to a significant reduction in neurite process length,
similar to the effect of the LRRK2 G2019S mutant expression
(Figures 2B and S2B).
We next sought more direct evidence of a physical interaction
between LRRK2 and RAB7L1 and thus performed coimmuno-
precipitation studies. Epitope-tagged forms of LRRK2 and
RAB7L1 (3xFlag-LRRK2 and GFP-RAB7L1) were cotransfected
into HEK293T cells, and after 48 hr, cell lysates were immuno-
precipitated with an anti-Flag antibody and then probed for
RAB7L1. Flag-immunoprecipitation of LRRK2 effectively copre-
cipitated RAB7L1 (Figure 3A). The interaction did not appear to
be altered by the presence of the G2019S mutation, or using a
kinase-dead variant K1906M of LRRK2 (MacLeod et al., 2006).
Similarly, immunoprecipitation of RAB7L1 with an antibody to
the GFP tag coprecipitated LRRK2 only in the presence of
GFP-RAB7L1 (Figure 3B). To probe for an interaction between
LRRK2 and RAB7L1 in a more physiological context, we exam-
ined RAB7L1 protein in brain lysates from transgenic mice that
harbor human wild-type LRRK2 or a familial PD mutant form of
LRRK2, R1441C, within a large bacterial artificial chromosome
(BAC) construct. Transgenic LRRK2 is broadly expressed
throughout the CNS of these mice, although at relatively low
levels (Figure S3A). Brain tissue lysates were immunoprecipi-
tated for LRRK2 protein with a rabbit monoclonal antibody.
Western blotting of the lysates for RAB7L1 demonstrated coim-
munoprecipitation of RAB7L1 (Figure 3C).
In vitro fluorescence microscopy studies were consistent
with the presence of RAB7L1 and LRRK2 in common subcellular
compartments. GFP-tagged RAB7L1, transfected into SH-SY5Y
cells, localized primarily to the Golgi apparatus (as identified
with the Golph4 marker), as well as along tubular structures
emerging from Golgi apparatus, consistent with prior reports
(Spano` et al., 2011). LRRK2 staining appeared more diffuse
than RAB7L1, but there was significant overlap (Figure 3D). In
contrast to the wild-type form, the RAB7L1 CA or IN mutant
forms appeared more diffusely localized through the cytoplasm,
as did a RAB7L1 alternative transcript (AT) deficient in the pre-
dicted GTP-binding region (Figure 3D; see below); accumulation
of the IN and AT mutant proteins was significantly reduced
(Figures 3D and S3B).
In Vivo Analysis of a LRRK2-RAB7L1 Pathway
in Drosophila Dopamine Neurons
To pursue potential mechanisms of LRRK2 pathology in vivo,
we established a Drosophila model. Although transgenic
mouse models expressing mutant LRRK2 have been widely
described (Andres-Mateos et al., 2009; Li et al., 2009; Piccoli
et al., 2011; Tong et al., 2009), these do not show consistent
neurodegenerative phenotypes. Dopamine neuron-selective
expression of human familial PD-associated G2019S mutant
LRRK2—using either a tyrosine hydroxylase (TH) (Friggi-Grelin
et al., 2003) or dopa decarboxylase (DDC) promoter-Gal4 driver
(Fischer et al., 1988)—induced premature mortality of young
adult animals (Figure 4A; data not shown; nontransgenic
mean lifespan 37.1 days ± 1; G2019S mean lifespan 4.8 days ±0.2), akin to previous reports (Ng et al., 2009). In contrast, trans-
genic expression of wild-type human LRRK2 did not lead to
a discernible phenotype. Furthermore, expression of the mutant
G2019S LRRK2 transgene in several other cell types, including
motor neurons, eye tissues, or muscles (using a variety of
promoter-Gal4 driver constructs; data not shown), failed to
lead to a discernible effect on survival or otherwise (data not
shown).
We subsequently performed a targeted screen for potential
genetic modifiers of the LRRK2 G2019S mutant phenotype,
based on the hypothesis that LRRK2maymodify a specific intra-
cellular trafficking process, and focused on Rab family genes. A
series of 16 Drosophila Rab genes, (see Table S4; out of 33
identified in Drosophila), or CA or IN forms of these (Zhang
et al., 2007), were investigated. Briefly, LRRK2 G2019S mutants
were mated with a panel of previously described transgenic
Drosophila strains that allow for overexpression of wild-type
(WT) or constitutively active (CA), forms of the Rab genes (Zhang
et al., 2007), using a standard balancer chromosome-based
mating scheme. Coexpression of a majority of these Rab trans-
genes with LRRK2 within dopamine neurons produced no effect
on the survival of animals coexpressing LRRK2 G2019S (Fig-
ure 4A; Table S4). In contrast, overexpression of wild-type and
CA forms of the Drosophila RAB7L1 ortholog (termed lightoid)
afforded a dramatic rescue of the LRRK2 G2019S premature
mortality phenotype (mean lifespan 24.0 days ± 1 for the CA; Fig-
ure 4A). Of note, among the other Rabs screened, only Rab7 led
to a statistically significant—albeit much weaker—survival
benefit (mean lifespan 14.3 days ± 0.6). Rab1, which was previ-
ously found to rescue a defect in vesicular trafficking to the Golgi
apparatus in a-syn overexpression models of PD (Cooper et al.,
2006), did not rescue the LRRK2 defect, suggesting distinct
mechanisms.
Next, dopamine neuron survival at the dorsomedial posterior
protocerebral (PPM1) and dorsolateral posterior protocerebral
(PPL1) clusters of Drosophila CNS mushroom bodies was quan-
tified in terms of the loss of expression of a dopamine neuron-
specific nuclear localization signal (NLS)-GFP marker protein,
using fluorescent confocal microscopy analysis of whole
mounted tissue. Expression of LRRK2 G2019S, but not the WT
form, led to the preferential loss of neurons in the dorsomedial
cluster, reminiscent of the phenotype in otherDrosophilamodels
of PD (Feany and Bender, 2000). Coexpression of CA RAB7L1
rescued the LRRK2 G2019S dopamine neuron loss phenotype
(Figure 4B). Deficiency of theRAB7L1 ortholog (in lightoid homo-
zygous mutants) selectively in dopamine neurons by expression
of an siRNA construct (Dietzl et al., 2007), led to a significant loss
of dopamine neurons (Figure 4B).
PARK16 Risk Variants Modify RAB7L1 Splicing and
Expression
The combination of human brain transcriptomic, human genetic,
and model system studies support a role for PARK16, and
specifically the PARK16 locus gene RAB7L1, in a pathway with
LRRK2. We next sought to query possible molecular mecha-
nisms at play at the PARK16 locus that may be responsible for
a link between common genetic variants, RAB7L1 function,
and PD risk. A challenge to this is that typically many variantsNeuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc. 429
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Figure 3. Evidence of a RAB7L1-LRRK2 Complex
(A) Immunoprecipitation (IP) analysis ofRAB7L1 from lysates of HEK293T cells transfectedwith plasmids encoding aGFP-RAB7L1 fusion protein (or vector alone)
and a 3xflag (3FL) epitope-tagged LRRK2 construct (either wild-type [WT], G2019S [GS], K1906M [KM], or empty vector). IP with an anti-flag antibody was
followed with immunoblot (IB) analysis with an anti-GFP or an anti-LRRK2 antibody as indicated. Arrowheads indicate the expected protein sizes.
(B) Coimmunoprecipitation of LRRK2 with RAB7L1 from lysates of HEK293T cells transfected with a plasmid encoding a 3xflag LRRK2 construct and a plasmid
encoding a GFP-RAB7L1 fusion protein (either WT, CA, IN, or GFP only).
(C) Immunoprecipitation using an anti-LRRK2 antibody from whole brain lysates of nontransgenic (NT), LRRK2 wild-type transgenic (WT), LRRK2 R1441C (RC)
transgenic, or LRRK2 knockout (/) mice. IB was subsequently performed for RAB7L1, RAB11, and LRRK2.
(D) Subcellular colocalization of RAB7L1 and LRRK2. Human neuroblastoma SH-SY5Y cells were transfected with GFP-tagged RAB7L1 vectors (in green;
either WT, CA, or IN forms, as well as a RAB7L1 construct lacking exon 2 and 3 and corresponding to an alternatively spliced RAB7L1 transcript, ‘‘AT’’) and a
(legend continued on next page)
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Figure 4. RAB7L1 Rescues Lethality and Dopamine Neuron Loss in a Drosophila Model of LRRK2 G2019S Neurodegeneration
(A) Modifier screen for suppressors of an early adult lethality phenotype seen with expression of LRRK2 G2019S selectively in tyrosine hydroxylase (TH)-positive
dopamine neurons. Left, a panel of 16 Drosophila RAB transgenes was screened (of 31 total; see Table S3). Adult survival (days posteclosion) curves are
presented for individual strains harboring different Rabs along with the LRRK2 G2019S transgene. Nontransgenic survival curve is shown for comparison. n > 25
for all conditions. Right, adult survival (days posteclosion) of Drosophila is presented in the context of transgenic expression of LRRK2 (WT or G2019S), with or
without RAB7L1 (WT, CA, or IN), using a tyrosine hydroxylase promoter GAL4 driver for dopaminergic neuron expression. Nontransgenic survival is also shown
for comparison. n > 25 for all conditions. ***p < 0.001 by ANOVA followed by Tukey’s HSD post hoc analysis.
(B) Left: confocal microscopy ofmushroombodies of the CNS from transgenicDrosophila as in (A), with dopaminergic neuron nuclei visualized using an additional
marker transgene, a nuclear localization sequence (NLS)-GFP fusion, also driven by TH-Gal4. Right: quantitation of surviving dopaminergic neurons in the PPM1
and PPL1 clusters of Drosophila CNSmushroom bodies. Means are displayed; error bars represent SEM. ***p < 0.001 by ANOVA followed by Tukey’s HSD post
hoc analysis.
See also Figure S4 and Table S4.
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s Diseaseat a given chromosomal location are so closely associated (in
‘‘linkage dysequilibrium’’) so as to make impossible the identifi-
cation of which is truly ‘‘causal’’ rather than just coincidental.
On reanalysis of existing genome-wide splicing data from human
lymphoblasts (Montgomery et al., 2010), the PD-associated
PARK16 haplotype was found to be associated with alternative
splicing of RAB7L1, characterized by the skipping of exons 2
and 3. We note that a common SNP variant within the PARK16
locus, rs1572931, that is in linkage dysequilibrium with SNP
rs947211 (Hamza et al., 2010) and thus similarly linked to PD
risk, falls precisely within regulatory sequences for splicing at
the Intron1-exon2 boundary (Figure 5A). Akin to the lymphoblast
transcriptome splicing data, our analysis of a set of human3xflag-tagged LRRK2 vector (in red, left panel). Subcellular localization was determ
TheCA form leads to a reduced localization to theGolgi apparatus.Colocalization i
LRRK2/Golph4stainingoverlap (upper, lower, andmiddle right panels, respectively
See also Figure S3.cortical brain samples revealed that the rs1572931 genotype is
similarly associated with modified splicing of RAB7L1 in human
forebrain (Figures 5B and S5A), where the protective PARK16
haplotype is associated with increased exon 2 inclusion in
RAB7L1 mRNA. Based strictly on human gene expression
data, we cannot directly assign a causal role for SNP
rs1572931 in altered splicing of RAB7L1 (as other SNPs in
linkage disequilibrium could be responsible for the observed
association). We thus sought to evaluate the causal effect of
rs1572931 using minigene reporter vectors that harbor either
the risk-associated or protective allele at rs1572931, but are
otherwise identical (Figures 5Cii and S5B). Upon transfection
into SH-SY5Y human neuroblastoma cells, the rs1572931 riskined by immunostaining with amarker for the Golgi apparatus (Golph4 in blue).
s evaluatedbyquantifying the fractionofRAB7L1/Golph4,RAB7L1/ LRRK2, and
).Results representmean±SEM(n=15per group). Scalebar represents10mM.
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Figure 5. PARK16 PD Risk-Associated Variants Modify RAB7L1 Splicing and Protein Accumulation
(A) Exonic structure of the human RAB7L1 gene.
(B) Analysis of RAB7L1 alternative splicing in human cortical brain samples. The rs1572931 allele G, linked to the PD high-risk haplotype (R), is associated with
an increase in the fraction of RAB7L1 transcripts that lack the exon 2 to exon 3 junction region (termed exon 2 skipping; presented relative to the extent of
exon 2 skipping seen in carriers of the rs1572931 protective allele A; quantified by qrtPCR using primers as depicted by red and black arrows in (A) detecting
respectively the amount of total and unskipped RAB7L1 mRNA; n = 15 and 57 for P and R respectively; details in Table S6). *p < 0.05; **p < 0.01; ***p < 0.001
by two-tailed t test.
(C) (i) Schematic of predicted splice site enhancer and silencer motifs upstream of RAB7L1 exon2 and affected by rs1572931 variants G (associated with
increased PD risk, ‘‘R’’) and A (protective, ‘‘P,’’ associatedwith decreased PD risk). (ii) Structure of aminigene construct to assess the effect of rs1572931 variants
on RAB7L1 exon2 inclusion in vitro. Green arrows indicate the position of the primers used to assess exon 2 inclusion.
(D) Impact of PARK16 variants on splicing in vitro. The rs1572931 allele G (associated with increased PD risk, R; relative to the allele A associated with
decreased PD risk, P) leads to a relative decrease in RAB7L1 exon 2 inclusion in transfected human SH-SY5Y cells as assess by PCR gel quantification (pictures
in Figures S5D and S5E; n = 6/group). *p < 0.05; **p < 0.01; ***p < 0.001 by two-tailed t test.
(E) Impact of rs1572931 on RAB7L1protein level in human cortical brain samples. rs1572931 allele G is associated with a decrease in RAB7L1 protein level in
non-PD postmortem human cortical brain samples, as assessed by western blot from individuals homozygous for the risk allele (R, n = 25) and from carriers of the
protective allele (P, n = 13). Mean levels are displayed; errors bars are SEM. *p < 0.05; **p < 0.01; ***p < 0.001 by linear regression analysis.
See also Figure S5 and Table S6.
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s Diseaseallele led to increased RAB7L1 exon 2 skipping relative to the
protective allele (Figures 5D and S5C–S5E).
Exon skipping is predicted to lead to the formation of a trun-
cated form of RAB7L1 protein that lacks the predicted
GTP-binding domain in the amino-terminal region (Figure S5C).
Overexpression of this truncated form leads to low level
accumulation of a shortened protein product (Figure S3B), and
reduced localization to the Golgi apparatus (Figure 3D); although
the shortened product can bind with LRRK2 protein (Figure 3B),
expression of this truncation mutant in primary neurons failed432 Neuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc.to rescue the reduced neurite length phenotype associated
with G2019S mutant LRRK2 (Figure S5F), whereas expression
of the wild-type RAB7L1 effectively rescued the phenotype.
Consistent with these in vitro findings, we observed a significant
reduction in full-length RAB7L1 protein in cerebral cortex tissue
from unaffected individuals who carry the PARK16 risk allele,
when compared to noncarrier individuals (Figure 5E). We note
that a similar reduction is seen in PD patient cerebral cortex
tissue regardless of the PARK16 genotype. This appears specific
to PD, as no such decrease is observed in tissue from patients
Neuron
RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s Diseasesuffering from other neurodegenerative disorders examined
(frontotemporal dementia or amyotrophic lateral sclerosis) who
do not carry the PARK16 risk allele (Figure 5E). Taken together,
these findings argue in favor of a posttranscriptional (splicing)
mechanism of action for the PARK16 PD risk variant’s impact
on RAB7L1 levels. However, given the linkage disequilibrium
structure of the region, we cannot exclude additional transcrip-
tional regulatory effects (Gan-Or et al., 2012).
Lysosomal Changes and Retromer-Associated Sorting
Defects in LRRK2 and RAB7L1 Mutant Neurons
We sought to pursue a cellular role for the LRRK2-RAB7L1
pathway. Prior studies have broadly implicated both of these
gene products in intracellular sorting (Sakaguchi-Nakashima
et al., 2007; Spano` et al., 2011). Expression of the LRRK2
G2019S clinical mutation in rat primary neurons induced lyso-
somal swelling, as quantified by immunostaining for the lyosomal
marker LAMP2 or using the lysosomotropic dye Lysotracker,
consistent with our prior work and other studies (Dodson et al.,
2012; MacLeod et al., 2006; Stafa et al., 2012) (Figure 6A; data
not shown). In addition to lysosomal enlargement, there was
significant reduction in lysosomal accumulation of the cation-
independent mannose 6-phosphate receptor (MPR) in terms of
the fraction of LAMP2-positive structures stained with MPR. As
MPR is required also for the recruitment of lysosomal hydro-
lases, its deficiency is predicted to lead to functional lysosomal
deficits. Knockdown of RAB7L1 was similarly associated with
swollen lysosomes and reduced lysosomal MPR, whereas over-
expression of RAB7L1 suppressed the lysosomal phenotypes in
the context of LRRK2 G2019S expression (Figure 6A).
MPR is typically recycled between the endolysosome com-
partment and the Golgi apparatus by the retromer complex
(Arighi et al., 2004; Bonifacino and Hurley, 2008; Skinner and
Seaman, 2009; St. George-Hyslop et al., 2009). Given the primary
apparent localization of RAB7L1 to the Golgi apparatus (Fig-
ure 3D), as well as the enrichment of LRRK2 at this organelle (Fig-
ure 3D) (Stafa et al., 2012), we hypothesized that the lysosomal
compartment defects described above may be secondary to
altered retromer mediated trafficking machinery between these
organelles (BonifacinoandHurley,2008;Seaman,2004).Analysis
of Golgi structures by immunostaining with the Golph4 marker in
primary neurons transfected with either LRRK2 G2019S or
shRNA for RAB7L1 did not reveal evidence of gross structural
changes, but MPR colocalization at the Golph4-positive Golgi
apparatus structures was significantly reduced (Figure 6B).
Accumulation of MPR at early endosomes, assessed by costain-
ingwith themarker early endosomal antigen-1 (EEA1; Figure 6C),
did not appear altered, whereas accumulation at the cell surface
appeared increased (data not shown). The total areas of Golph4,
MPR, or EEA1 staining were unaffected by G2019S LRRK2
expression or RAB7L1 knockdown (Figures 6A–6C).
The retromer complex is required for retrograde transport
of selective cargo—including MPR—between lysosomes and
the Golgi apparatus, through endosomal intermediates, in
mammalian cells (Figure 6D) (Bonifacino and Hurley, 2008;
St. George-Hyslop et al., 2009), and defects can lead to lyso-
somal swelling(Arighi et al., 2004). Furthermore, rare mutations
in a retromer component, VPS35, were recently linked to rarefamilial forms of PD (Vilarin˜o-Gu¨ell et al., 2011; Zimprich et al.,
2011). Knockdown of VPS35 in primary neuron cultures led to
reduced MPR colocalization with the Golgi apparatus and with
late endosomes/lysosome markers (Figures 6A and 6B), as
previously described (Skinner and Seaman, 2009). Similarly,
expression of a familial PD-associated mutation in VPS35,
D620N (Vilarin˜o-Gu¨ell et al., 2011; Zimprich et al., 2011), phe-
nocopied the MPR missorting phenotype of G2019S mutant
LRRK2 expression or VPS35 knockdown (Figures 6A and 6B),
suggesting a dominant negative mode of action which is consis-
tent with a predicted structural alteration of a retromer complex
interaction motif (Vilarin˜o-Gu¨ell et al., 2011; Zimprich et al.,
2011). In contrast, overexpression of wild-type VPS35, which
promotes trafficking through the retromer pathway, suppressed
the altered MPR localization seen with G2019S mutant LRRK2
expression (Figures 6A and 6B). Thus, although it is likely that
the LRRK2-RAB7L1 pathway impacts intracellular sorting
processes in addition to retromer complex function, retromer
component overexpression is sufficient to rescue the deficits
associated with defects in the LRRK2-RAB7L1 pathway.
We further investigated the functional relationship of VPS35
with the LRRK2-RAB7L1 pathway in the context of neurite
process maintenance. In rat primary neurons, overexpression
of VPS35 alone did not directly modify neurite process length,
but effectively suppressed the loss of neurite processes in the
context of LRRK2 G2019S expression or RAB7L1 knockdown
(Figure 7A). In contrast, knockdown of VPS35 with an shRNA
vector, or expression of the VPS35 D620N mutant form, led to
neurite process length reduction that phenocopied the effect of
LRRK2 G2019S expression. In vivo analysis in the Drosophila
CNS further supported a role for retromer dysfunction in the
context of LRRK2-RAB7L1 pathway defects. Overexpression
of Drosophila VPS35 in Drosophila CNS dopamine neurons
rescued the LRRK2 G2019S dopamine neuron loss phenotype
(Figure 7B), and similarly extended the lifespan of G2019S
LRRK2 mutant-expressing flies (data not shown). In contrast,
knockdown of VPS35 selectively in Drosophila TH-positive
dopamine neurons led to significant cell loss and a reduced life-
span (Figure 7B).
Reduction in Retromer Complex Component Levels
in the Context of LRRK2-RAB7L1 Pathway Defects
We next sought to pursue potential molecular mechanisms for
the apparent defects in retromer pathway function in the context
of LRRK2 G2019S mutation or RAB7L1 knockdown. In mouse
Neuro-2A (N2A) neuroblastoma cells, expression of LRRK2
G2019S or knockdown of RAB7L1 led to a significant reduction
in the levels of accumulated VPS35 as well as VPS29, a second
component of the retromer complex (Figure 7C). Levels of retro-
mer complex components are dependent on the formation of the
entire complex, which also includes VPS29, and thus loss of any
complex component is predicted to impact levels of others (Kim
et al., 2010). Analysis of transgenic mouse total brain tissue over-
expressing the R1441C mutant form of LRRK2 also led to
a significant reduction in the accumulation of VPS35, VPS29,
and VPS26 (Figure 7D).
Although the precise mechanism by which the LRRK2-
RAB7L1 pathway impacts retromer complex function and levelsNeuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc. 433
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Figure 6. RAB7L1 and LRRK2 Modulate Lysosome and Golgi Apparatus Sorting in a Retromer-Dependent Manner
(A–C) Analysis of MPR sorting in primary rat neuron cultures transfected with vectors encoding LRRK2 G2019S mutant (GS), RAB7L1, VPS35, or VPS35 D620N;
or with shRNA plasmids forVPS35,RAB7L1, or vector only, cotransfectedwith GFP vector for visualization and immunostained forMPR aswell as either theGolgi
marker Golph4 (A, upper panel), the lysosome marker Lamp2 (B, upper panel) or with the early endosome marker EEA1(C, upper panel). MPR colocalization with
either the Golph4 or LAMP2marker was reduced with G2019S LRRK2, VPS35 D620N, or knockdown of either RAB7L1 or VPS35 (A, lower panel; B, lower panel).
(legend continued on next page)
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s Diseaseremains to be determined, coimmunoprecipitation studies of
LRRK2 with VPS35 support a direct interaction between these
proteins: lysates from SH-SY5Y cells coexpressing epitope-
tagged V5-LRRK2 (or vector) and eGFP-VPS35 forms, were
immunoprecipitated for the eGFP tag. Subsequent western
blotting revealed copurification of LRRK2 with eGFP-VPS35
(Figure 7E). Similarly, immunoprecipitation of LRRK2 from
LRRK2 transgenic mouse brain tissue led to the coprecipitation
of endogenous VPS35 (Figure 7F). It remains to be determined
whether the interactions of LRRK2 with VPS35 and RAB7L1
are within a single complex or multiple complexes.
To relate those findings to sporadic PD, we analyzed VPS35
levels in PD or unaffected human brain tissue. We first conduct-
ed a meta-analysis of substantia nigra (SN) mRNA expression
levels in five publically available microarray gene expression
data sets from patients and controls (Table S5; totally 144 indi-
viduals, 63 unaffected individuals and 81 PD patients), and
observed a highly significant decrease in VPS35 mRNA levels
(Figure 7G). Such a decrease was also observed in gene expres-
sion data from laser-microdissected PD SN dopamine neurons,
when compared to similar cells isolated from unaffected patients
(Figure 7G), as well as in PD cerebral cortex tissue (Figures 7H
and 7I), but not in PD globus pallidus interna tissue, which is
typically spared. Taken together, these results support a role
for retromer deficiency in PD pathology, although the mecha-
nism for altered retromer component transcript levels remains
to be determined.
DISCUSSION
Using a brain transcriptomic approach as a starting point, we
provide evidence that the impacts of several distinct PD risk-
associated common genetic variants are overlapping, even in
unaffected PD-free carrier tissue. This points to a convergent
pathway of action for such variants. Focusing subsequently on
LRRK2 and the PARK16 locus gene RAB7L1, in vitro and in vivo
studies support a functional interaction: these gene products
bound together and functionally interacted in the regulation of
neurite process length in vitro, as well as in the context of dopa-
mine neuron survival in vivo. We emphasize that the impact of
LRRK2 and PARK16 variants on brain gene expression was
observed even in unaffected carriers of the PARK16 or LRRK2
locus risk variants; this suggests the existence of a predisease
prodromal state in such carriers, that favors subsequent
progression.
Themost prominent neuronal sorting phenotypeswe observed
in the context of PD-associated LRRK2-RAB7L1 pathway
changeswere at lysosomes and theGolgi apparatus.Wehypoth-
esize that the proximal site of action for these proteins may be in
defective retromer function at the Golgi apparatus, given theThese manipulations also increased total LAMP2 staining (but not Golph4 staining
total organelle marker analyses are presented in the lower panels. Error bars rep
0.01; ***p < 0.001 for comparisons with ‘‘vector’’ group. ++p < 0.01; +++p < 0.001
HSD post hoc analysis.
(D) Schematic of cell sorting phenotype associated with defects in the LRRK2
accumulation at Golph4-positive structures (trans-golgi network [TGN]) and at LA
lysosomes appear swollen.enrichment of both proteins at this structure. Trafficking of MPR
to the Golgi apparatus—a function of the retromer complex—is
defective, and associated with lysosomal swelling. Although the
precise mechanism of retromer dysfunction is unclear, retromer
pathway components including VPS35 appear reduced in the
context of LRRK2 mutation or RAB7l1 knockdown. Recently
described familial PD-associated clinical mutations in VPS35
phenocopy thedeficits associatedwithLRRK2-RAB7L1pathway
dysfunction, whereas overexpression of VPS35 can rescue such
deficits. We also note that RAB7 was identified in both our
in vitro and in vivo screens of RAB proteins as suppressing the
phenotype of LRRK2mutant pathology, albeit less robustly than
RAB7L1. RAB7 is the only RAB protein previously implicated in
the regulation of retromer function (Rojas et al., 2008).
Prior studies have supported a role for LRRK2 in vesicular traf-
ficking (Biskup et al., 2006; Dodson et al., 2012; Higashi et al.,
2009; MacLeod et al., 2006; Stafa et al., 2012). However, cellular
mechanisms of LRRK2 relevant in human brain—and in the
context of PD or PD risk variants—have remained unclear. The
studies herein are unusual in pursuing a PD genetic pathway
using both human brain and model system analyses. We identify
a genetic interaction between LRRK2 andRAB7L1 in the context
of PD risk, and variants at the loci of these genes impact the brain
transcriptome in an overlapping manner. Subsequent cell and
animal model studies support a model where LRRK2 and
RAB7L1 defects may modify intracellular sorting and retromer
pathway function.
It is possible that PD-related defects in LRRK2 and RAB7L1
adversely impact aspects of vesicular trafficking in addition
to retromer function. Nonetheless, inducing retromer function
appears sufficient to rescue cellular defects and neuronal
survival in these models, suggesting a therapeutic venue in PD
patients. It is interesting to note that VPS35 deficits, as well as
genetic variants at retromer complex receptor loci such as
SORLA (Rogaeva et al., 2007), have also been associated
with a second major neurodegenerative disorder, Alzheimer’s
disease (Muhammad et al., 2008); this suggests a broader role
for retromer dysfunction in neurodegeneration. We speculate
that perhaps different cargos may be involved in the association
of the retromer pathway with distinct pathological processes in
Alzheimer’s and Parkinson’s. To this end, it is of interest to inves-
tigate the impact of such retromer dysfunction on a-syn and
other proteins associated with PD pathology.
EXPERIMENTAL PROCEDURES
Drosophila Methods
Drosophila were cultured by standard methods on yeast-cornmeal-agar
medium at 25C. WT and mutant G2019S LRRK2 transgenes were expressed
specifically in catecholaminergic neurons, including dopamine neurons, using
the Gal4-UAS system described (Fischer et al., 1988). Driver lines used include). Scale bar represents 10 mm. Quantifications of the MPR colocalization and of
resent SEM; n > 10 cells in three independent wells per group. *p < 0.05; **p <
for comparisons with ‘‘LRRK2 G2019S’’ group by ANOVA followed by Tukey’s
-RAB7L1 pathway or knockdown of the VPS35 retromer component. MPR
MP2-positive structures (lysosomes and late endosomes [LE]) is reduced, and
Neuron 77, 425–439, February 6, 2013 ª2013 Elsevier Inc. 435
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Figure 7. Evidence of Retromer Insufficiency in the Context of LRRK2-RAB7L1 Pathway Defects
(A) Transfection of rat primary cortical neuron cultures with a wild-type (WT) VPS35 expression vector rescued the reduced neurite length phenotype associated
with LRRK2 G2019S (GS) mutant expression or with Rab7L1 (R7L1) knockdown. Overexpression of a familial PD mutant VPS35 D620N vector leads to reduced
neurite length relative to vector alone. Knockdown of VPS35 by shRNA leads to similarly reduced neurite length relative to vector alone, which is not rescued by
Rab7L1 overexpression (n = 20 neurons in four cultures per group). *p < 0.05; **p < 0.01 for ANOVA followed by Tukey’s HSD post hoc analysis.
(B) Left: confocal microscopy of mushroom bodies of the CNS from transgenic Drosophila, with dopaminergic neuron nuclei visualized using a TH-Gal4-driven
nuclear localization sequence (NLS)-GFP fusion. Right: quantitation of surviving dopaminergic neurons in the PPM1 and PPL1 clusters of Drosophila CNS
mushroom bodies. *p < 0.05; **p < 0.01 for ANOVA followed by Tukey’s HSD post hoc analysis.
(C) Relative quantification by western blot of VPS35 (left) or VPS29 (right) protein levels in lysates frommouse neuroblastoma (N2a) cells transfected with vectors
encoding VPS35 WT, VPS35 shRNA, VPS35 D620N, LRRK2 WT, LRRK2 G2019S (GS), RAB7L1, RAB7L1 shRNA, or vector control (n = 3/group). *p < 0.05;
**p < 0.01 for ANOVA followed by Tukey’s HSD post hoc analysis.
(D) LRRK2 impacts the levels of retromer components in mouse brain. Relative quantification by western blotting of VPS35 (left), VPS29 (middle), and
VPS26 (right) levels in brain tissue samples from nontransgenic (nTg), LRRK2 wild-type (LRRK2-WT) and LRRK2 R1441C mutant (LRRK2-RC) BAC transgenic
mice (n = 3 /group).
(legend continued on next page)
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RAB7L1/LRRK2/VPS35 Pathway in Parkinson’s DiseaseOK6 (motor neuron), Gmr (eye), G14 (muscle), TH (dopaminergic neuron), and
DDC (dopaminergic neuron). A UAS-GFP::nuclear localization sequence
(NLS) marker was used to visualize nuclei of cells in which trangenes were
expressed (stock 4775 [w1118; P{UAS-GFP.nls}14], Drosophila Stock Center,
Bloomington, IN). For the RAB screen, UAS-LRRK2 (G2019S) transgenic
Drosophila, crossed with the TH-Gal4 driver, were screened against a UAS-
Rab transgenic library (Zhang et al., 2007). Crossings were typically performed
using standard balancer chromosome techniques. To generate strains in
which the homozygous LRRK2 transgene and another (Driver or marker)
transgene lay on the same chromosome (III), genetic recombination was using
standard techniques. AdultDrosophilamushroom bodies were dissected as in
Wu and Luo (2006) and imaged immediately, without fixation, using a Zeiss
LSM510 Meta confocal fluorescent microscope. For mortality curves, trans-
genic Drosophila surviving through adult metamorphosis were counted daily,
from the day of pupal eclosion onward.
Primary Neuron Cultures
All procedures with rats and mice were approved by the IACUC of the
Columbia UniversityMedical Center. Sprague-Dawley rat ormouse P1 primary
dissociated cortical cultures were prepared and transfected essentially as
described (Xia et al., 1996) with the following modifications: cells were plated
at high density,250,000 cells/cm2, in 24-well plates with 500 ml medium/well.
Culture medium used for plating cells was Neurobasal-A supplemented with
2% B-27 and 10% FBS. At 1 day after plating, medium was changed to
reduced serum (1% FBS+ added antimitotic agents: 70 mM uridine and
25 mM 5-fluorodeoxyuridine) and replaced weekly thereafter; for transfections
no DMSO was added to the transfection mixture, cells were not subjected to
glycerol shock, and a total of 3 mg plasmid DNA was used per well. Cells
were fixed in 4% PFA and immunostained with mouse a-RAB7L1 (Santa
Cruz, 1:100), and rabbit monoclonal a-LRRK2 (Michael J. Fox Foundation
MJFF4, 1:100), then with appropriate fluorescent secondaries (Jackson,
1:1,000–2,000). Neurite length and neurite puncta (defined as swellings >2
um in diameter) were counted for at least 20 neurons per condition. Mean
puncta number per neuron was normalized to total average neurite length
versus wild-type LRRK2 transfected cells. Fluorescent microscopy was per-
formed using a Nikon TE 2000-S microscope and a Zeiss LSM510 Meta
confocal microscope. Images were analyzed using Image-Pro Plus (Mediacy-
bernetics) software version 5.1.0.20.
Colocalization Analysis
Primary rat cortical neurons were cultured on glass coverslips, transfected,
and fixed as previously described in this methods section. Cells were immuno-
stained for MPR (Abcam #ab2733, 1:400), Golph4 (Abcam #ab28049, 1:500),
and Lamp2 (Sigma L0668, 1:500). Fluorescent microscopy was performed
using a Zeiss LSM510 Meta confocal microscope. Images were analyzed
using NIH ImageJ software version 1.45.
Cell Culture, Transfection, and Cytochemistry
HEK293T and SH-SY5Y cells were maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine serum and 1%(E) Immunoprecipitation (IP) analysis of RAB7L1 from lysates of SH-SY5Y cells
wild-type sequence (WT) or the familial PDmutant D620M (D620N) or vector alone
was followed with western immunoblot analysis with an anti-LRRK2 or anti-GFP
(F) IP using an anti-LRRK2 antibody fromwhole brain lysates of nontransgenic (NT
knockout (/) mice as in Figure 3D. Immunoblot was subsequently performed
(G) VPS35 mRNA levels in substantia nigra tissue as determined by meta-analy
individuals and 81 PD patients samples (left panel) and in laser-microdissected (L
10 PD patients samples (right panel, GEOGSE20141). Expression levels are norma
by Tukey’s HSD by two-tailed t-test.
(H) VPS35mRNA in cerebral cortex tissue as determined by high-throughput sequ
unaffected and 17 PD cerebral cortical tissue samples. Levels are expressed as re
by two-tailed t-test.
(I) VPS35 mRNA levels in globus pallidus interna (GP-I) samples (n = 10/group,
group. For all graphs means are displayed, error bars represent SEM.
See also Figure S6 and Table S5.penicillin/streptomycin at 37C in a 5%CO2 atmosphere. Transient expression
was performed by transfecting the plasmids using Lipofectamine2000
(Invitrogen) according to the manufacturer’s instructions. The transfected
SH-SY5Y cells grown on glass coverslips for 24 hr were fixed with 4% parafor-
maldehyde in PBS for 30 min, washed three times with PBS and subjected
to the observation of fluorescence. For immunostaining of Golgi, fixed cells
were blocked and permeabilized with PBS containing 0.1% Triton X-100
and 3% bovine serum albumin followed by incubation with anti-Golph4
polyclonal antibody (Abcam) and Alexa Fluor 555 goat anti-rabbit IgG (Invitro-
gen). Staining of nuclei was performed by using SYTOX Orange nucleic acid
stain (Invitrogen). Fluorescence was detected using Zeiss LSM 510 confocal
microscope.
Immunohistochemistry and Signal Quantification
LRRK2 R1441C or Wt BAC transgenic mice (Li et al., 2009) (Jackson Labora-
tory) were sacrificed and perfused immediately with 4%PFA for 20min. Brains
were cut by vibratome into sections 60 mm thick. Sections were blocked in
5% NDS overnight at 4 C, then incubated with primary antibodies overnight
at 4C. Antibodies used were sheep monoclonal a-TH (Pelfreeze, 1:500),
mouse a-RAB7L1 (Santa Cruz, 1:100), and rabbit monoclonal a-LRRK2
(Michael J. Fox Foundation MJFF4, 1:100). Sections were incubated at room
temperature for 2 hr with appropriate fluorescent secondaries (Jackson Labo-
ratories, 1:1,000). Microscopy was performed with a Zeiss LSM510 Meta
confocal. Fluorescence signal intensity was quantified using NIH ImageJ.
Human Autopsied Brain Samples
Cortical BA9 area brain samples were obtained from the New York Brain Bank
and are detailed in Table S6. Anonymous, deidentified tissue from the brain
bank was used.
Quantitative Real-Time RT-PCR
RT-qPCR was done as described in (Rhinn et al., 2008). RAB7L1 ratio was
quantified using DDCt method using the following primers pairs:
RAB7L1_Ex2_fw (CAGCAAACACTACAAGTCCACG)
RAB7L1_Ex3_rv (CAGCTGAAGCCGCACTATCTCG) and
RAB7L1_Ex4_fw (GACAGCAAGCTCACACTACCCA)
RAB7L1_Ex5_rv (TCTGTCCAACCTGTGAAACCGT) for human brain
samples.
Minigene Splicing Assay
The human SH-SY5Y neuroblastoma cell line (ATCC) was cultured following
ATCC’s instructions, plated at densities of 4.10e5 cells per well (48-well plates)
in wells coated with 0.1% gelatin (Specialty Media, Millipore) 24 hr prior to
transfections. Transfections were performed with Lipofectamine 2000 reagent
(Invitrogen) following manufacturer’s instructions. After transfection with plas-
mids encoding the reporter construct, RNA was extracted using miRNeasy kit
(QIAGEN) and reverse transcribed using Superscript III reverse transcriptase
(Invitrogen) following manufacturer’s instructions. The cDNA was amplified
by PCR using the following primers: GGAGGGCGTCTAGGGAATCGAG (Fw,transfected with plasmids encoding a GFP-VPS35 fusion protein with VPS35
, alongwith a LRRK2 construct or an empty vector. IPwith an anti-GFP antibody
antibody as indicated. Arrowheads indicate the expected protein sizes.
), LRRK2wild type transgenic (WT), LRRK2 R1441C (RC) transgenic, or LRRK2
for VPS35 and b-actin.
sis of five gene expression microarray data sets (Table S5) in 63 unaffected
MD) substantia nigra dopaminergic neurons from 8 unaffected individuals and
lized tomean of the unaffected group. *p < 0.05; **p < 0.01 for ANOVA followed
encing of the 30UTR ends of polyadenylatedmRNA transcripts on a cohort of 17
ads per million (rpm). *p < 0.05; **p < 0.01 for ANOVA followed by Tukey’s HSD
GEO GSE20146). Expression levels are normalized to mean of the unaffected
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(Rev., complementary to GFP CDS) and Accuprime high-fidelity polymerase
(Invitrogen) following the manufacturer’s instructions with a hybridization at
55C and an elongation step of 1 min.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2012.11.033.
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